alexa Cetuximab and Oral Mucositis: Is it Different from Oral Mucositis Caused by Other Drugs? | OMICS International| Abstract
ISSN: 2161-119X

Otolaryngology: Open Access
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • Otolaryngology 2013, Vol 3(4): 147
  • DOI: 10.4172/2161-119X.1000147

Cetuximab and Oral Mucositis: Is it Different from Oral Mucositis Caused by Other Drugs?

Daniela Musio1*, Francesca De Felice1, Nadia Bulzonetti1 and Vincenzo Tombolini1,2
1Dipartimento di Scienze Radiologiche Oncologiche e Anatomo-Patologiche, Cattedra di Radioterapia, Università di “Sapienza” Roma, , Italy
2Fondazione Spencer-Lorillard, Roma, , Italy
*Corresponding Author : Daniela Musio, Dipartimento di Scienze Radiologiche Oncologiche e Anatomo-Patologiche, Cattedra di Radioterapia, Università di “Sapienza” Roma, Viale Regina Elena 155, 00161 Roma, Italy, Tel: 06-49973404, Fax: 0649973411, Email: [email protected]

Received Date: Oct 09, 2013 / Accepted Date: Nov 09, 2013 / Published Date: Nov 18, 2013

Abstract

Purpose: To estimate frequency of oral mucositis in treatment for head and neck cancer with radiotherapy and concurrent cetuximab and to determine whether it has different characteristics from mucositis caused by other drugs.

Materials and methods: Subjects with locally advanced, primary non-metastatic, squamous cell carcinoma located in the oropharynx were treated with radiation therapy plus concomitant cetuximab. Results: None of patients received their full planned course of combination treatment due to excessive mucosal toxicity. All patients developed oral mucositis within about 10-15 days: it began directly, without escalation, as grade ≥ 3; it was associated with severe pain and trismus; it was never associated to specific supra-infections; the evolution and the consequent resolution of clinical discomfort required several days and the treatment with corticosteroids did not represent the solution formula.

Conclusion: Cetuximab induced oral mucositis have the following specific characteristics: time of onset, mode of clinical expression, severity, association with trismus and minimal response to corticosteroid therapy. Considering that the majority of studies do not reveal oral toxicity associated with cetuximab, future clinical trials should focus on specific topics to improve the definition of documented oral toxic effects.

Keywords: Cetuximab, Chemotherapy, Oral mucositis, Drugs

Citation: Musio D, De Felice F, Bulzonetti N, Tombolini V (2013) Cetuximab and Oral Mucositis: Is it Different from Oral Mucositis Caused by Other Drugs? Otolaryngology 3:147. Doi: 10.4172/2161-119X.1000147

Copyright: © 2013 Musio D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Recommended Conferences
Article Usage
  • Total views: 12760
  • [From(publication date): 11-2013 - Sep 22, 2020]
  • Breakdown by view type
  • HTML page views: 8907
  • PDF downloads: 3853
Top